{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:18:43Z","timestamp":1777119523670,"version":"3.51.4"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,7,15]]},"DOI":"10.2169\/internalmedicine.4360-24","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T17:10:49Z","timestamp":1735837849000},"page":"2114-2123","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Switching between Anti-CGRP Monoclonal Antibodies: A Detailed Monthly and Long-term Follow-up Study and Literature Review"],"prefix":"10.2169","volume":"64","author":[{"given":"Kota","family":"Oshima","sequence":"first","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Ihara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"},{"name":"Japanese Red Cross Ashikaga Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Takemura","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Ishizuchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Dental College Ichikawa General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23: 67, 2022.","DOI":"10.1186\/s10194-022-01431-x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Takizawa T, Ohtani S, Watanabe N, et al. Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol 22: 512, 2022.","DOI":"10.1186\/s12883-022-03041-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"4. Takizawa T, Ihara K, Watanabe N, et al. CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society. J Headache Pain 25: 39, 2024.","DOI":"10.1186\/s10194-024-01737-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"5. Ziegeler C, May A. Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class. Headache 60: 469-470, 2020.","DOI":"10.1111\/head.13729"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6. Porta-Etessam J, Gonz\u00e1lez-Garc\u00eda N, Guerrero \u00c1L, Garc\u00eda-Azor\u00edn D. Failure of monoclonal antibodies against CGRP or its receptor does not imply lack of efficacy of other drugs from the same class. Neurologia (Engl Ed) 36: 638-640, 2021.","DOI":"10.1016\/j.nrleng.2020.10.008"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7. Patier Ruiz I, S\u00e1nchez-Rubio Ferr\u00e1ndez J, C\u00e1rcamo Fonfr\u00eda A, Molina Garc\u00eda T. Early experiences in switching between monoclonal antibodies in patients with nonresponsive migraine in Spain: a case series. Eur Neurol 85: 132-135, 2022.","DOI":"10.1159\/000518899"},{"key":"7","doi-asserted-by":"publisher","unstructured":"8. Overeem LH, Peikert A, Hofacker MD, et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 42: 291-301, 2022.","DOI":"10.1177\/03331024211048765"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9. Doi S, Ito M, Takebayashi Y, Muramatsu K, Horikoshi M. Factorial validity and invariance of the 7-item generalized anxiety disorder scale (GAD-7) among populations with and without self-reported psychiatric diagnostic status. Front Psychol 9: 1741, 2018.","DOI":"10.3389\/fpsyg.2018.01741"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10. Muramatsu K, Maeda S, et al. Diagnostic Performance of the Japanese Version of the GAD-7 in Primary Care and Comparing its Accuracy with Other Language Versions. Medical Research Archives. European Society of Medicine 13: 2025.","DOI":"10.18103\/mra.v13i1.6247"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11. Muramatsu K, Miyaoka H, Kamijima K, et al. Performance of the Japanese version of the Patient Health Questionnaire-9 (J-PHQ-9) for depression in primary care. Gen Hosp Psychiatry 52: 64-69, 2018.","DOI":"10.1016\/j.genhosppsych.2018.03.007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12. Ohtani S, Watanabe N, Ihara K, et al. Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study. BMC Neurol 23: 404, 2023.","DOI":"10.1186\/s12883-023-03449-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13. Overeem LH, Lange KS, Fitzek MP, et al. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: a real-world cohort study. Front Neurol 14: 1154420, 2023.","DOI":"10.3389\/fneur.2023.1154420"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14. Fres\u00e1n-Restituto D, Lacalle-Fabo E, Mart\u00edn-Bujanda M, Sarobe-Carricas MT. Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one. Rev Neurol 76: 213-216, 2023.","DOI":"10.33588\/rn.7606.2022350"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15. Brice\u00f1o-Casado MDP, Gil-Sierra MD, De-La-Calle-Riaguas B. Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series. Eur J Hosp Pharm 30: e19, 2023.","DOI":"10.1136\/ejhpharm-2021-002946"},{"key":"15","doi-asserted-by":"publisher","unstructured":"16. Iannone LF, Burgalassi A, Vigani G, et al. Switching anti-CGRP (R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study. Cephalalgia 43: 1-11, 2023.","DOI":"10.1177\/03331024231189112"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17. Kaltseis K, Filippi V, Frank F, Eckhardt C, Schiefecker A, Broessner G. Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an Austrian case series. BMC Neurol 23: 174, 2023.","DOI":"10.1186\/s12883-023-03203-9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18. Straube A, Broessner G, Gaul C, et al. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study. J Headache Pain 24: 59, 2023.","DOI":"10.1186\/s10194-023-01593-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19. Lambru G, Caponnetto V, Hill B, et al. Long-term effect of switching from an anti-CGRP receptor to an anti-CGRP ligand antibody in treatment-refractory chronic migraine: a prospective real-world analysis. Neurotherapeutics 20: 1284-1293, 2023.","DOI":"10.1007\/s13311-023-01394-0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20. Ihara K, Ohtani S, Watanabe N, et al. Switching between anti-calcitonin gene-related peptide monoclonal antibodies: a comparison of monthly and quarterly dosing. J Neurol Sci 453: 120811, 2023.","DOI":"10.1016\/j.jns.2023.120811"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21. Suzuki S, Suzuki K, Shiina T, Haruyama Y, Hirata K. Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Front Neurol 14: 1220285, 2023.","DOI":"10.3389\/fneur.2023.1220285"},{"key":"21","doi-asserted-by":"crossref","unstructured":"22. Talbot J, Stuckey R, Wood N, Gordon A, Crossingham G, Weatherby S. Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab. Eur J Hosp Pharm 32: 178-185, 2025.","DOI":"10.1136\/ejhpharm-2023-003779"},{"key":"22","doi-asserted-by":"crossref","unstructured":"23. Suliman R, Santos V, Al Qaisi I, et al. Effectiveness of switching CGRP monoclonal antibodies in non-responder patients in the UAE: a retrospective study. Neurol Int 16: 274-288, 2024.","DOI":"10.3390\/neurolint16010019"},{"key":"23","doi-asserted-by":"crossref","unstructured":"24. Suzuki K, Suzuki S, Shiina T, et al. Real-world effectiveness of erenumab in Japanese patients with migraine. Heliyon 10: e26568, 2024.","DOI":"10.1016\/j.heliyon.2024.e26568"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25. Ihara K, Ohtani S, Watanabe N, et al. Response to letter: "Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule" by Suzuki et al. J Neurol Sci 455: 122785, 2023.","DOI":"10.1016\/j.jns.2023.122785"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26. Suzuki S, Suzuki K, Shiina T, Kobayashi S, Shioda M, Hirata K. Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule. J Neurol Sci 455: 122786, 2023.","DOI":"10.1016\/j.jns.2023.122786"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27. Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache 46 (Suppl 4): S182-S191, 2006.","DOI":"10.1111\/j.1526-4610.2006.00602.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28. Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21: 61, 2020.","DOI":"10.1186\/s10194-020-01127-0"},{"key":"28","doi-asserted-by":"crossref","unstructured":"29. Holzer P, Holzer-Petsche U. Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide's motor-stimulating and prosecretory function in the intestine. Front Physiol 12: 820006, 2022.","DOI":"10.3389\/fphys.2021.820006"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30. Silberstein SD, Reshef S, Cohen JM, et al. Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: a retrospective analysis using the FDA adverse events reporting system. Adv Ther 40: 445-459, 2023.","DOI":"10.1007\/s12325-022-02346-4"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31. Wells-Gatnik WD, Martelletti P. Switching CGRP (r) MoAbs in migraine: what evidence? Expert Opin Biol Ther 24: 327-333, 2024.","DOI":"10.1080\/14712598.2024.2354386"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/14\/64_4360-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T03:50:13Z","timestamp":1752897013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/14\/64_4360-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":30,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4360-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"article-number":"4360-24"}}